Lupin Limited (LUPIN) — Announcement Announcement
📢 Key Event
Lupin receives China approval for Oseltamivir Phosphate Oral Suspension
💡 Investor Takeaway
This entry into China opens a major new revenue market for Lupin's global expansion.
Lupin announced that China's National Medical Products Administration approved its Abbreviated New Drug Application for Oseltamivir Phosphate Oral Suspension in partnership with Yabao Pharmaceuticals, marking Lupin's first product entry into the Chinese market and expanding access to pediatric influenza treatment.
📄 View Original Announcement (PDF)
About Lupin Limited (LUPIN)
Healthcare · Pharmaceuticals & Biotechnology · Listed on NSE
Market Cap: ₹1,04,071.47 Cr
P/E: 36.2
Source: Stock Announcements. Analysis by StockFin.ai. For informational purposes only — not investment advice.